TECOTABART VEDOTIN
UNII 9GK5GYD8DQ

Substance Identification & Data

This profile provides standardized clinical and technical data for Tecotabart Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 9GK5GYD8DQ.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2823357-33-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

9GK5GYD8DQ

CAS Registry Number

2823357-33-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TECOTABART VEDOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C185853

National Cancer Institute reference terminology for clinical and research data.

INN ID

13032

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Tecotabart vedotin

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tecotabart Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Tecotabart vedotin

Common Names & Synonyms

Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE

H-gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV3-48*01 (88.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, G1v7 CH2 D3, E117 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 S3>D (241), I117>E (334) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)], (222-220')-disulfide with L-kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (90.1%) -IGKJ2*02 (90.9%), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (159'), V101 (197') (114'-220')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 222, 228, 231, 220', 222'', 228'', 231'' and 220''' with radical group (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin)

Immunoglobulin G1 [241-aspartic acid,334-glutamic acid], anti-(human/Mus musculus/Macaca/Rattus claudin CLDN18.2) (human-Mus musculus monoclonal LM-102 γ1-chain), disulfide with human-Mus musculus monoclonal LM-102 κ-chain, dimer, tetrakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ)], humanized monoclonal antibody; conjugated on an average of 4 cysteinyl residues via a cleavable linker to monomethylauristatin E (MMAE)

tecotabart vedotin [INN]